US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

210.78

-21.2100-9.14%

Post-market: 212.671.89+0.90%18:13 EDT

Volume:424.24K

Turnover:92.13M

Market Cap:563.73M

PE:- -

High:229.00

Open:229.00

Low:210.16

Close:231.99

52wk High:341.93

52wk Low:102.35

Shares:2.67M

Float Shares:2.67M

Volume Ratio:0.68

T/O Rate:15.86%

Dividend:0.90

Dividend Rate:0.43%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Astrana Health's Unit Agrees Partnership With Verda Healthcare in Arizona and Texas

MT Newswires Live

China Resources Double-Crane Pharmaceutical Gets FDA Approval for Lupus Drug Clinical Trial

MT Newswires Live

Table: CHC Healthcare Group Sep Rev Nt$506.4m vs Nt$527.9m

Echo IQ Appeals US FDA Decision on EchoSolv HF; Shares Up 8%

MT Newswires Live

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Granted FDA Fast Track Designation for First-Line Advanced or Metastatic Biliary Tract Cancer

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Solventum Corporation (SOLV)

HLB Resubmits Liver Cancer Drug Application to U.S. FDA After Complete Response Letter

Echo IQ Escalates FDA Appeal Over EchoSolv HF 510(k) Ruling

Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and Nektar Therapeutics (NKTR)

FDA Clears Acrux’s Path to Phase III and Potential Exclusivity for Female Testosterone Spray

Nanjing Leads Biolabs Wins Second U.S. FDA Fast Track for Cancer Drug LBL-024

Ascelia Pharma Charts New Path for Orviglance After FDA Meeting

How Investors May Respond To Supernus Pharmaceuticals (SUPN) FDA Approval For ONAPGO

Simply Wall St.

Why Ryman Healthcare Bears Were Right Before The Drop

Simply Wall St.

Should FDA Fast Track Entry Require Action From Arrowhead Pharmaceuticals (ARWR) Investors?

Simply Wall St.

Wall Street Analysts Are Bullish on Top Healthcare Picks

Healthcare Realty Trust (HR), What Is Behind The Fresh Attention?

Simply Wall St.

Did Oceania Healthcare's Fall Catch You Out? What Bears Saw

Simply Wall St.

Lancang Residents: 2027 Urban and Rural Resident Basic Medical Insurance Enrollment Opens Today

FDA Warning Letter Could Be A Game Changer For Neogen Stock (NEOG)

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au.tigermarketb.com/stock/LABU/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"Direxion Daily S&P Biotech Bull 3x Shares","latestPrice":210.78,"timestamp":1791921600000,"preClose":231.99,"halted":0,"volume":424239,"hourTrading":{"tag":"盘后","latestPrice":212.67,"preClose":210.78,"latestTime":"18:13 EDT","volume":11503,"amount":2449941.72355,"timestamp":1791929617661,"change":1.89,"changeRate":0.008967,"amplitude":0.010684},"delay":0,"changeRate":-0.09142635458424936,"floatShares":2674486,"shares":2674486,"eps":0,"marketStatus":"Post-Mkt","change":-21.21,"latestTime":"10-13 18:14:49 EDT","open":229,"high":229,"low":210.1596,"amount":92127304.27383001,"amplitude":0.081212,"askPrice":213.03,"askSize":588,"bidPrice":212.3,"bidSize":24,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791936000000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":231.99,"sharesOutstanding":3074486,"nav":242.822,"aum":649423578.22,"dividendRate":0.004293,"bidAskSpread":0.002692,"preHourTrading":{"tag":"盘前","latestPrice":228,"preClose":231.99,"latestTime":"09:29 EDT","volume":2274,"amount":529315.02324,"timestamp":1791898190029,"change":-3.99,"changeRate":-0.017199,"amplitude":0.03664},"postHourTrading":{"tag":"盘后","latestPrice":212.67,"preClose":210.78,"latestTime":"18:13 EDT","volume":11503,"amount":2449941.72355,"timestamp":1791929617661,"change":1.89,"changeRate":0.008967,"amplitude":0.010684},"volumeRatio":0.675251,"impliedVol":0.9697,"impliedVolPercentile":0.7131},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":2674486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.675251,"shares":2674486,"dividePrice":0.9048,"high":229,"amplitude":0.081212,"preClose":231.99,"low":210.1596,"week52Low":102.3547,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":210.78,"committee":-0.921569,"eps":0,"divideRate":0.004293,"volume":424239,"delay":0,"ttmEps":0,"open":229,"prevYearClose":159.39,"prevWeekClose":243.09,"prevMonthClose":265.79,"prevQuarterClose":265.79,"fiveDayClose":230.95,"twentyDayClose":250.4,"sixtyDayClose":249.1},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2674873717","title":"Astrana Health's Unit Agrees Partnership With Verda Healthcare in Arizona and Texas","url":"https://stock-news.laohu8.com/highlight/detail?id=2674873717","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674873717?lang=en_us&edition=fundamental","pubTime":"2026-10-12 17:21","pubTimestamp":1791796868,"startTime":"0","endTime":"0","summary":"Astrana Health's (ASTH) AstranaCare Partners unit has signed a new partnership with Verda Healthcare in Arizona and Texas, Verda said Saturday.The companies will work together to improve the quality and accessibility of healthcare in underserved communities, Verda said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4196","BK4137","XLV","ASTH","LU0128526141.USD","LABU","HCSG","LU0029874061.USD","XBI","BK4585","BK4581","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674034827","title":"China Resources Double-Crane Pharmaceutical Gets FDA Approval for Lupus Drug Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2674034827","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674034827?lang=en_us&edition=fundamental","pubTime":"2026-10-12 16:02","pubTimestamp":1791792123,"startTime":"0","endTime":"0","summary":"China Resources Double-Crane Pharmaceutical  subsidiary Beijing Double-Crane Runchuang Technology received U.S. FDA clinical trial approval for its DC7001A capsules, according to a Monday filing with the Shanghai bourse.The drug is indicated for systemic lupus erythematosus, the filing said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0175","600062","BK0188","BK4588","BK0185","BK4585","LABU","BK0028","BK0239","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674827321","title":"Table: CHC Healthcare Group Sep Rev Nt$506.4m vs Nt$527.9m","url":"https://stock-news.laohu8.com/highlight/detail?id=2674827321","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674827321?lang=en_us&edition=fundamental","pubTime":"2026-10-12 15:40","pubTimestamp":1791790800,"startTime":"0","endTime":"0","summary":"Source: Taiwan Stock Exchange This content was automatically published based on data and/or text from the original source. For feedback, write to singaporeeditors@dowjones.com.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0029874061.USD","LABU","BK4137","XBI","HCSG","BK4581","XLV","LU0128526141.USD","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674823161","title":"Echo IQ Appeals US FDA Decision on EchoSolv HF; Shares Up 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674823161","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674823161?lang=en_us&edition=fundamental","pubTime":"2026-10-12 11:30","pubTimestamp":1791775810,"startTime":"0","endTime":"0","summary":"Echo IQ  filed an administrative appeal challenging the US Food and Drug Administration's  decision that its EchoSolv HF device is not substantially equivalent for 510 clearance, according to a Monday Australian bourse filing.The appeal has been accepted, and the US FDA Ombudsman has been duly notified, per the filing.The company expects to gain greater clarity on EchoSolv HF's regulatory pathway following an FDA meeting anticipated within the next 30 days, the filing added.The company's shares rose 8% in recent Monday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","EIQ.AU","BK4588","BK7016","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674284057","title":"Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Granted FDA Fast Track Designation for First-Line Advanced or Metastatic Biliary Tract Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2674284057","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674284057?lang=en_us&edition=fundamental","pubTime":"2026-10-12 09:47","pubTimestamp":1791769620,"startTime":"0","endTime":"0","summary":"Second FDA Fast Track Designation for Opamtistomig Underscores Its Potential in Immunologically Cold TumorsNANJING, China, Oct.  12, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Bi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/12/3378545/0/en/leads-biolabs-opamtistomig-pd-l1-4-1bb-bispecific-antibody-granted-fda-fast-track-designation-for-first-line-advanced-or-metastatic-biliary-tract-cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTCI","BITY","CBTJ","COAL","BTGD","MAXI","BCCC","BTCL","QBF","BTRN","DEFI","BFJL","ODD","BRRR","HODL","FBTC","BTCW","BEGS","BITX","BTFX","BETH","AEIS","IBIT","YBIT","GBTC","ORR","CBXJ","BAGY","XHB","BITB","HCC","MNRS","OC","MSBT","YBTC","LABU","BFAP","OOQB","BETE","DFII","ARKY","STCE","NCIQ","BTCZ","CRPT","SBIT","BTF","BTC","CBXY","CBOJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674844386","title":"Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Solventum Corporation (SOLV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2674844386","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674844386?lang=en_us&edition=fundamental","pubTime":"2026-10-12 07:20","pubTimestamp":1791760808,"startTime":"0","endTime":"0","summary":"Analysts fell to the sidelines weighing in on Alnylam Pharma (ALNY) and Solventum Corporation (SOLV) with neutral ratings, indicating that the expe...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alnylam-pharma-alny-and-solventum-corporation-solv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alnylam-pharma-alny-and-solventum-corporation-solv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU0114720955.EUR","BK4585","LU0882574055.USD","SOLV","BK4581","BK4198","LU0128526141.USD","BK4137","XBI","PBE","LU0889565916.HKD","BK4588","GNMX","LU0320765992.SGD","ALNY","XLV","LU0109394709.USD","LABU","HCSG","BK4548","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674360844","title":"HLB Resubmits Liver Cancer Drug Application to U.S. FDA After Complete Response Letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2674360844","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674360844?lang=en_us&edition=fundamental","pubTime":"2026-10-12 07:12","pubTimestamp":1791760358,"startTime":"0","endTime":"0","summary":"HLB Co., Ltd. ( ($KR:028300) ) has provided an update. HLB Co., Ltd., via its U.S. subsidiary Elevar Therapeutics, Inc., is advancing an oncology p...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/hlb-resubmits-liver-cancer-drug-application-to-u-s-fda-after-complete-response-letter?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/hlb-resubmits-liver-cancer-drug-application-to-u-s-fda-after-complete-response-letter?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674844339","title":"Echo IQ Escalates FDA Appeal Over EchoSolv HF 510(k) Ruling","url":"https://stock-news.laohu8.com/highlight/detail?id=2674844339","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674844339?lang=en_us&edition=fundamental","pubTime":"2026-10-12 07:04","pubTimestamp":1791759855,"startTime":"0","endTime":"0","summary":"The latest update is out from EchoIQ Limited ( ($AU:EIQ) ). Echo IQ has lodged a request for supervisory review with the U.S. Food and Drug Adminis...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/echo-iq-escalates-fda-appeal-over-echosolv-hf-510k-ruling?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/echo-iq-escalates-fda-appeal-over-echosolv-hf-510k-ruling?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IQ","BK4552","BK4588","BK4526","BK4108","BK4585","BK4531","BK4505","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674841786","title":"Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and Nektar Therapeutics (NKTR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2674841786","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674841786?lang=en_us&edition=fundamental","pubTime":"2026-10-12 07:01","pubTimestamp":1791759679,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Insmed (INSM) and Nektar Therapeutics (NKTR) with bu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-insmed-insm-and-nektar-therapeutics-nktr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-insmed-insm-and-nektar-therapeutics-nktr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0053671581.USD","LU0109394709.USD","LABU","LU0128526141.USD","NKTR","XBI","BK4139","BK4585","BK4588","BK4007","LU0320765992.SGD","HCSG","BK4137","LU0889565916.HKD","INSM","BK4581","XLV","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674731841","title":"FDA Clears Acrux’s Path to Phase III and Potential Exclusivity for Female Testosterone Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2674731841","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674731841?lang=en_us&edition=fundamental","pubTime":"2026-10-12 06:52","pubTimestamp":1791759161,"startTime":"0","endTime":"0","summary":"Acrux ( ($AU:ACR) ) has shared an announcement. Acrux Limited, an Australian pharmaceutical developer of transdermal drug delivery products, is adv...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fda-clears-acruxs-path-to-phase-iii-and-potential-exclusivity-for-female-testosterone-spray?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fda-clears-acruxs-path-to-phase-iii-and-potential-exclusivity-for-female-testosterone-spray?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","LNGR","BK4585","BK4588","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674184111","title":"Nanjing Leads Biolabs Wins Second U.S. FDA Fast Track for Cancer Drug LBL-024","url":"https://stock-news.laohu8.com/highlight/detail?id=2674184111","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674184111?lang=en_us&edition=fundamental","pubTime":"2026-10-12 06:37","pubTimestamp":1791758260,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. Class H ( ($HK:9887) ) has issued an announcement. Nanjing Leads Biolabs said its core drug candidate LBL-024, an a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nanjing-leads-biolabs-wins-second-u-s-fda-fast-track-for-cancer-drug-lbl-024?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nanjing-leads-biolabs-wins-second-u-s-fda-fast-track-for-cancer-drug-lbl-024?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674810599","title":"Ascelia Pharma Charts New Path for Orviglance After FDA Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2674810599","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674810599?lang=en_us&edition=fundamental","pubTime":"2026-10-11 20:32","pubTimestamp":1791721949,"startTime":"0","endTime":"0","summary":"Ascelia Pharma AB ( ($SE:ACE) ) just unveiled an announcement. Ascelia Pharma has received official minutes from its Type A meeting with the U.S. F...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ascelia-pharma-charts-new-path-for-orviglance-after-fda-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ascelia-pharma-charts-new-path-for-orviglance-after-fda-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4554","LU0516422366.SGD","LU0979878070.USD","SG9999013478.USD","SG9999002414.USD","LU2065169927.USD","BK4585","LU1242518857.USD","LU0289960550.SGD","LU0499858438.USD","LU2045819591.USD","SG9999002604.SGD","BK4588","SG9999014484.SGD","SG9999014492.USD","SGXZ58947870.SGD","BK4566","LU0441851309.USD","LU0572939691.SGD","LU2065171402.SGD","SG9999013486.USD","LU1048588211.SGD","LU2238330802.EUR","SG9999001135.SGD","LU0499858602.USD","BK4220","BK4548","LABU","LU0823039010.USD","LU2125910500.SGD","SE","SG9999005177.SGD","BK4085","LU0532188223.SGD","SG9999004360.SGD","IE0034224299.USD","LU0823038988.USD","SG9999002406.SGD","LU2152927971.USD","LU0737861269.HKD","LU0516422440.USD","IE00BD6J9T35.USD","LU2543165471.USD","LU2177674079.SGD","LU0516423174.USD","LU1839390173.USD","FDNI","SG9999002620.SGD","LU0175139822.USD","LU0572940350.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674495817","title":"How Investors May Respond To Supernus Pharmaceuticals (SUPN) FDA Approval For ONAPGO","url":"https://stock-news.laohu8.com/highlight/detail?id=2674495817","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674495817?lang=en_us&edition=fundamental","pubTime":"2026-10-11 18:33","pubTimestamp":1791714796,"startTime":"0","endTime":"0","summary":"Supernus Pharmaceuticals recently received FDA approval for ONAPGO, a treatment for motor fluctuations in Parkinson's disease, expanding its central nervous system portfolio.\nThis new approval adds another commercial product alongside Qelbree, GOCOVRI and Oxtellar XR, which may influence how investors view Supernus Pharmaceuticals' earning power and product diversity.\nWe will now assess how Supernus Pharmaceuticals' investment narrative could evolve in light of the new ONAPGO approval in...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-supn/supernus-pharmaceuticals/news/how-investors-may-respond-to-supernus-pharmaceuticals-supn-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-supn/supernus-pharmaceuticals/news/how-investors-may-respond-to-supernus-pharmaceuticals-supn-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","BK4588","ISBC","LABU","BK4007","BK4585","SUPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674481245","title":"Why Ryman Healthcare Bears Were Right Before The Drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2674481245","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674481245?lang=en_us&edition=fundamental","pubTime":"2026-10-11 14:30","pubTimestamp":1791700250,"startTime":"0","endTime":"0","summary":"If you had looked at Ryman Healthcare on 1 January 2026, with ageing demographics headlines and bold margin turnaround stories in mind, it might have felt hard to step aside. Holding Ryman Healthcare from the start of the year would have meant a 42.2% loss, including dividends. With that outcome now on the table, which early assumptions about debt, regulation and housing exposure deserved closer scrutiny before committing capital?\nNarratives are how investors here put a case on the record,...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6033000-choice1-card/1788938511465","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6033000-choice1-card/1788938511465"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/nz/healthcare/nzx-rym/ryman-healthcare-shares/news/why-ryman-healthcare-bears-were-right-before-the-drop","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/nz/healthcare/nzx-rym/ryman-healthcare-shares/news/why-ryman-healthcare-bears-were-right-before-the-drop","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LABU","BK8050","XBI","RYM.NZ","BK4581","XLV","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674819344","title":"Should FDA Fast Track Entry Require Action From Arrowhead Pharmaceuticals (ARWR) Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2674819344","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674819344?lang=en_us&edition=fundamental","pubTime":"2026-10-11 10:35","pubTimestamp":1791686137,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals reported that the FDA granted plozasiran, marketed as REDEMPLO, entry into the STAR pilot program for an upcoming sNDA in severe hypertriglyceridemia, enabling Priority Review and a targeted expedited timeline without using the company’s previously acquired Priority Review Voucher.\nThe STAR decision indicates that regulators view plozasiran as potentially offering substantial clinical benefit over current therapies. This supports Arrowhead Pharmaceuticals’ position...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/should-fda-fast-track-entry-require-action-from-arrowhead-ph","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/should-fda-fast-track-entry-require-action-from-arrowhead-ph","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ARWR","BK4585","ISBC","BK4588","LABU","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674890467","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2674890467","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674890467?lang=en_us&edition=fundamental","pubTime":"2026-10-11 00:40","pubTimestamp":1791650406,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on HCW Biologics (HCWB) and Atossa Therapeutics (ATOS) ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-376?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-376?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4539","XLV","LABU","BK4581","BK4139","LU0029874061.USD","BK4585","BK4588","HCSG","HCWB","XBI","LU0128526141.USD","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674894037","title":"Healthcare Realty Trust (HR), What Is Behind The Fresh Attention?","url":"https://stock-news.laohu8.com/highlight/detail?id=2674894037","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674894037?lang=en_us&edition=fundamental","pubTime":"2026-10-10 18:39","pubTimestamp":1791628785,"startTime":"0","endTime":"0","summary":"Why Healthcare Realty Trust’s Transformation Plan Matters Now\nHealthcare Realty Trust (HR) has been pushing its 2.0 transformation ahead of schedule, repairing core systems and reshaping its balance sheet through asset sales and targeted debt reduction.\nThese steps, combined with efforts to improve leasing execution and deepen relationships with major health systems, are intended to support property level performance and more selective capital allocation across its portfolio.\nRecent trading...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9621071-choice2-card/1788985081922","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9621071-choice2-card/1788985081922"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/real-estate/nyse-hr/healthcare-realty-trust/news/healthcare-realty-trust-hr-what-is-behind-the-fresh-attentio","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/real-estate/nyse-hr/healthcare-realty-trust/news/healthcare-realty-trust-hr-what-is-behind-the-fresh-attentio","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["HR","BK4585","SRET","LABU","TSPA","BK4203","XBI","BK4588","CDIG","SPHQ","TACU","BK4581","XLV","BK4225"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674189144","title":"Did Oceania Healthcare's Fall Catch You Out? What Bears Saw","url":"https://stock-news.laohu8.com/highlight/detail?id=2674189144","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674189144?lang=en_us&edition=fundamental","pubTime":"2026-10-10 17:21","pubTimestamp":1791624078,"startTime":"0","endTime":"0","summary":"Oceania Healthcare looked like a classic ageing‑population story at the start of 2026, with bulls pointing to modern villages and cost savings while bears warned about debt, staff expenses, and softer core cash flow. Holding Oceania Healthcare from the start of the year would have meant a 28.2% loss, including dividends. If you had been weighing those opposing views back in January, which warning signs around shrinking profit and falling net margin would have stood out most?\nOn Simply Wall...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6033000-choice1-card/1788938511465","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6033000-choice1-card/1788938511465"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/nz/healthcare/nzx-oca/oceania-healthcare-shares/news/did-oceania-healthcares-fall-catch-you-out-what-bears-saw","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/nz/healthcare/nzx-oca/oceania-healthcare-shares/news/did-oceania-healthcares-fall-catch-you-out-what-bears-saw","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LABU","BK4588","OCA.NZ","XBI","XLV","BK4585","BK8050","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160216796","title":"Lancang Residents: 2027 Urban and Rural Resident Basic Medical Insurance Enrollment Opens Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1160216796","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160216796?lang=en_us&edition=fundamental","pubTime":"2026-10-10 16:21","pubTimestamp":1791620492,"startTime":"0","endTime":"0","summary":"Lancang residents, enrollment for the 2027 urban and rural resident basic medical insurance program begins on October 10. This is a major annual matter concerning the healthcare protection of every...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","LABU","XLV","BK4581","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674989958","title":"FDA Warning Letter Could Be A Game Changer For Neogen Stock (NEOG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2674989958","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674989958?lang=en_us&edition=fundamental","pubTime":"2026-10-10 14:31","pubTimestamp":1791613888,"startTime":"0","endTime":"0","summary":"Neogen reported first quarter revenue of US$222.8 million and a net loss of US$11.9 million, raised full year 2027 revenue guidance, and separately received an FDA warning letter over contaminated HYCOAT(R) veterinary product lots that were already recalled after serious horse fatalities.\nThe FDA letter highlights extensive manufacturing and labeling violations around HYCOAT(R), pointing to potential remediation spend, quality system upgrades, and reputational pressure that directly...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6022000-choice1-card/1788992506868","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6022000-choice1-card/1788992506868"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-neog/neogen/news/fda-warning-letter-could-be-a-game-changer-for-neogen-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-neog/neogen/news/fda-warning-letter-could-be-a-game-changer-for-neogen-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NEOG","BK4198","BK4588","LABU","R","BK4022","LU2211817866.USD","BK4585","BK4232"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":20,"pageCount":4,"totalSize":399,"code":"91000000","status":"200"}]}}